

-
- ❑ **Wyeth-Ayerst Canada Inc.** provided an \$80 million (1993) investment in capital expansion of its fine chemical plant in Brandon, Manitoba.

Since 1988, the private sector has increased its R&D expenditures in the area of university and institutional research in Canada. This has effectively leveraged the sector's R&D investment and has given it access to a variety of networks, which keeps the sector at the forefront of technology. Some examples follow.

- ❑ **Amgen Canada Inc.** has invested \$100 million to establish the Amgen Research Institute in Toronto. The Institute is affiliated with the Ontario Cancer Institute/Princess Margaret Hospital, Canada's largest cancer treatment and research centre.
- ❑ **Bayer Inc.** is investing \$1.35 million to support basic research in the progression and treatment of heart failure under the MRC/PMAC Health Program. The research will be carried out at The Toronto Hospital. The MRC will be donating an additional \$600 000 in funding support.
- ❑ **Bristol-Myers Squibb Pharmaceutical Group** gave \$10.3 million in January 1995 to the Samuel Lunenfeld Research Institute at Toronto's Mount Sinai Hospital. The funds will support the research by the Institute's molecular and development biologists, and will be used to establish the Centre for Human Genome Research and Molecular Medicine at the Institute. This initiative alone will create more than 150 research positions.
- ❑ **Ciba-Geigy Canada Ltd.** has given \$547 600 to the Mount Sinai Hospital, Toronto, toward research into osteoporosis.
- ❑ **Glaxo Wellcome Inc.** invested \$2.9 million in support of a study into the treatment of a form of lung cancer and establishment of a tumour bank. The company also pledged \$2.6 million over the next three years in support of the Glaxo Heritage Research Institute at the University of Alberta. This brings Glaxo's total investment in this new facility to \$7.6 million. The Institute is conducting medical research into better treatments for AIDS and Hepatitis B.
- ❑ **Merck-Frosst Canada Inc.** has donated \$200 000 to establish a Research Chair in Pharmaco-epidemiology at the University of Saskatchewan.
- ❑ **Sandoz Canada Inc.** has entered into a five-year, \$4-million agreement with The Toronto Hospital. The funding will support organ transplantation research and patient management, and will establish a research chair in transplantation.
- ❑ **Schering Canada Inc.** has donated \$559 000 toward clinical trials in HIV patients at various hospitals and universities across Canada.